Granulocyte Donation with GCSF

Clinical Center

Investigators

Linked publications, trials & patents

Abstract

Since the last annual report, two new subjects enrolled onto the protocol. To date, a total of 125 healthy volunteers have been enrolled and signed informed consent to donate granulocytes. Since the last annual report (August 2022) two (2) new subjects enrolled onto the protocol; a total of 186 healthy volunteers have been enrolled and signed informed consent, including 125 to donate granulocytes and 61 to participate in the two sub-studies. During this time, 7 donors donated a total of 9 products for two 2 different recipients, 6 and 3, respectively. Most active donors did not donate due to lack of need, scheduling conflicts, or ABO or HLA incompatibilities. Overall, donor retention in the program is 50%, with donor attrition due to moving away from the Bethesda area or loss of interest. In 28% of collection procedures, donors were stimulated with G-CSF and dexamethasone, 72% with G-CSF only. Donors reported symptoms included bone pain, irritability, fatigue, fever, chills, and nausea. These effects were expected consequences of G-CSF and/or dexamethasone administration and are described in the protocol and the consent.